Gibtulio Met 12.5mg/1000mg Tablet
Product Info
Prescription required | Yes |
Marketer | Lupin Ltd |
Active Ingredient | Empagliflozin (12.5mg) + Metformin (1000mg) |
Storage | Store below 30°C |
Habit Forming | No |
Therapeutic Class | ANTI DIABETIC |
User Rating | 4.3 |
User Reviews | 327 |
FAQ
Gibtulio Met 12.5mg/1000mg Tablet Reviews
Gibtulio Met 12.5mg/1000mg should be taken with food at any time of day but you should try to take it at the same time every day. The dose will be decided by your doctor. Don’t stop taking it without asking your doctor. If you do, your blood sugar levels may increase and put you at risk of serious complications like kidney damage and blindness. This medicine is only part of a treatment program that should include a healthy diet, regular exercise, and weight reduction as advised by your doctor.
The most common side effects of this medicine include taste changes, nausea, vomiting, diarrhea, joint pain, urinary tract infection, and yeast infections. Drinking plenty of fluids while using it will help prevent dehydration. Some people may develop fungal infections in the genital area. Maintaining good hygiene can help prevent this.
Before taking this medicine, inform your doctor if you have any kidney or liver problems or a urinary tract infection or if you are on water pills (diuretics). Pregnant or breastfeeding women should also consult their doctor before taking it. Avoid excessive alcohol intake while taking it as this may increase the risk of developing some side effects. Monitor your blood sugar levels regularly while taking this medicine.
How Gibtulio Met 12.5mg/1000mg Tablet Works
How to Use Gibtulio Met 12.5mg/1000mg Tablet
Benefits of Gibtulio Met 12.5mg/1000mg Tablet
- In Treatment of Type 2 diabetes mellitus: Gibtulio Met 12.5mg/1000mg is a medicine that helps to control high blood glucose (sugar) levels. It helps get rid of extra glucose from your body through urine. Lowering blood glucose levels is an essential part of managing diabetes. If you can control the level, you will reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems and loss of limbs. This medicine will reduce the risk of dying from cardiovascular disease if you have type 2 diabetes and already have cardiovascular disease. Taking this medicine regularly along with proper diet and exercise will help you live a normal, healthy life. You should keep using it for as long as it is prescribed because it is protecting your future health.
Uses of Gibtulio Met 12.5mg/1000mg Tablet
- Treatment of Type 2 diabetes mellitus
Gibtulio Met 12.5mg/1000mg Tablet Side Effects
Safety Tips
Quick Tips
- It also reduces the risk of heart attack, heart failure or other cardiovascular events.
- You should continue to exercise regularly, eat a healthy diet, and take your other diabetes medicines (if prescribed) along with Gibtulio Met 12.5mg/1000mg.
- It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines, alcohol or if you delay or miss a meal. Monitor your blood sugar level regularly.
- Always carry some sugary food or fruit juice with you in case you experience hypoglycemia symptoms such as cold sweats, cool pale skin, tremor, and anxious feeling.
- Practice good genital hygiene to prevent yeast or urinary tract infections
- You have been prescribed this combination medicine as it can control blood sugar better than metformin alone.
- It may cause your body to lose too much fluid (dehydration) or you to urinate more often. Drink plenty of water and stay hydrated.
- Take it with food to lower your chance of having an upset stomach.
References
- Empagliflozin and metformin hydrochloride extended-release (Synjardy XR) [FDA Prescribing Information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016.
- Empagliflozin and Metformin hydrochloride [Patient Information Sheet]. Ahmedabad, Gujarat: TORRENT PHARMACEUTICAL LIMITED; 2022.
- Empagliflozin and metformin hydrochloride tablets (Synjardy) [Product Monograph]. Burlington, ON: Boehringer Ingelheim (Canada) Ltd.; 2020.